These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 35710321)
1. Hypertriglyceridaemia: an update. Wierzbicki AS; Kim EJ; Esan O; Ramachandran R J Clin Pathol; 2022 Dec; 75(12):798-806. PubMed ID: 35710321 [TBL] [Abstract][Full Text] [Related]
2. Volanesorsen in the Treatment of Familial Chylomicronemia Syndrome or Hypertriglyceridaemia: Design, Development and Place in Therapy. Esan O; Wierzbicki AS Drug Des Devel Ther; 2020; 14():2623-2636. PubMed ID: 32753844 [TBL] [Abstract][Full Text] [Related]
3. Demystifying the management of hypertriglyceridaemia. Watts GF; Ooi EM; Chan DC Nat Rev Cardiol; 2013 Nov; 10(11):648-61. PubMed ID: 24060958 [TBL] [Abstract][Full Text] [Related]
5. Hypertriglyceridaemia due to genetic defects in lipoprotein lipase and apolipoprotein C-II. Fojo SS; Brewer HB J Intern Med; 1992 Jun; 231(6):669-77. PubMed ID: 1619390 [TBL] [Abstract][Full Text] [Related]
6. The advantages and pitfalls of genetic analysis in the diagnosis and management of lipid disorders. Berberich AJ; Hegele RA Best Pract Res Clin Endocrinol Metab; 2023 May; 37(3):101719. PubMed ID: 36641373 [TBL] [Abstract][Full Text] [Related]
7. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score". Moulin P; Dufour R; Averna M; Arca M; Cefalù AB; Noto D; D'Erasmo L; Di Costanzo A; Marçais C; Alvarez-Sala Walther LA; Banach M; Borén J; Cramb R; Gouni-Berthold I; Hughes E; Johnson C; Pintó X; Reiner Ž; van Lennep JR; Soran H; Stefanutti C; Stroes E; Bruckert E Atherosclerosis; 2018 Aug; 275():265-272. PubMed ID: 29980054 [TBL] [Abstract][Full Text] [Related]
8. Anti-sense oligonucleotide therapies for the treatment of hyperlipidaemia. Wierzbicki AS; Viljoen A Expert Opin Biol Ther; 2016 Sep; 16(9):1125-34. PubMed ID: 27248482 [TBL] [Abstract][Full Text] [Related]
9. Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature. Ito MK Atherosclerosis; 2015 Oct; 242(2):647-56. PubMed ID: 26296750 [TBL] [Abstract][Full Text] [Related]
10. Severe Hypertriglyceridaemia and Chylomicronaemia Syndrome-Causes, Clinical Presentation, and Therapeutic Options. Bashir B; Ho JH; Downie P; Hamilton P; Ferns G; Datta D; Cegla J; Wierzbicki AS; Dawson C; Jenkinson F; Delaney H; Mansfield M; Teoh Y; Miedzybrodzka Z; Haso H; Durrington PN; Soran H Metabolites; 2023 Apr; 13(5):. PubMed ID: 37233662 [TBL] [Abstract][Full Text] [Related]
11. Volanesorsen to treat severe hypertriglyceridaemia: A pooled analysis of randomized controlled trials. Calcaterra I; Lupoli R; Di Minno A; Di Minno MND Eur J Clin Invest; 2022 Nov; 52(11):e13841. PubMed ID: 35851450 [TBL] [Abstract][Full Text] [Related]
13. Hypertriglyceridaemia in adolescents may have serious complications. Korf M; Zöllner EW; Solomon GEA; Zemlin AE; Marais AD S Afr Med J; 2022 Apr; 112(5):307-312. PubMed ID: 35587241 [TBL] [Abstract][Full Text] [Related]
14. Long-term clinical outcomes and management of hypertriglyceridemia in children with Apo-CII deficiency. Yoldas Celik M; Canda E; Yazici H; Erdem F; Yuksel Yanbolu A; Atik Altinok Y; Pariltay E; Akin H; Kalkan Ucar S; Coker M Nutr Metab Cardiovasc Dis; 2024 Jul; 34(7):1798-1806. PubMed ID: 38503616 [TBL] [Abstract][Full Text] [Related]
15. Severe hypertriglyceridaemia as a result of familial chylomicronaemia: the Cape Town experience. Pouwels ED; Blom DJ; Firth JC; Henderson HE; Marais AD S Afr Med J; 2008 Feb; 98(2):105-8. PubMed ID: 18350203 [TBL] [Abstract][Full Text] [Related]